
Inflection Point Acquisition Corp. II, Direxion Daily MU Bull 2X Shares, Cue Biopharma, Esperion Therapeutics, and Akanda are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations—typically roughly $300 million to $2 billion, though exact cutoffs vary by index or data provider. They often offer higher growth potential but come with greater volatility, lower liquidity, and higher business risk than larger-cap stocks, so investors usually treat them as a higher-risk, growth-oriented part of a portfolio. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.
Inflection Point Acquisition Corp. II (IPXX)
Read Our Latest Research Report on IPXX
Direxion Daily MU Bull 2X Shares (MUU)
Cue Biopharma (CUE)
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Read Our Latest Research Report on CUE
Esperion Therapeutics (ESPR)
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Read Our Latest Research Report on ESPR
Akanda (AKAN)
Read Our Latest Research Report on AKAN
See Also
- MarketBeat’s Top Five Stocks to Own in May 2026
- The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches
- Visa Soars Post-Earnings; Outlook Positive Despite AI Risks
- The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat
- These 3 AI Stocks Just Crushed Earnings: Still Time To Buy?
- After 15% L3Harris Price Drop, Is It Time to Buy or Time to Fly?
